Biomedical subjects

V Dhawan

Publications and source records attributed to V Dhawan.

At least 73 records · Page 4Linked to original sources

PubMed1996

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.

Flurodopa (FDOPA) is an analogue of L-di-hydroxyphenylalanine (L-dopa) used to assess the nigrostriatal dopamine system in vivo with positron emission tomography (PET). However, FDOPA/PET quantitation is complicated by the presence of the 3-O-methyl-FDOPA (3OMFD) fraction in brain and plasma. Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake. We performed FDOPA/PET with and without the OR-611 preadministration in six Parkinson's disease (PD) patients. We measured the time-course of the plasma FDOPA and 3OMFD fractions using high-pressure liquid chromatography (HPLC). We calculated striato-occipital ratios (SOR), and estimated the striatal FDOPA uptake rate constant graphically using the plasma FDOPA and occipital tissue time activity curves (KiFD and KiOCC, respectively). We also estimated striatal dopa decarboxylase (DDC) activity (k3D) using a model incorporating independent measurements of 3OMFD transport kinetic rate constants. With the preadministration of OR-611, the pharmacological efficiency in plasma was prolonged significantly (21.1-37.7%; p < 0.01). We also observed significant mean elevations in SOR and KiOCC by 21.8 and 53.5%, respectively (p < 0.05). KiFD and k3D did not show significant change. We conclude that OR-611 prolongs the circulation time of FDOPA in the plasma but does not alter rate constants for striatal FDOPA uptake or decarboxylation.

Adult↗

PubMed1996

Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations.

Some cases of familial amyotrophic lateral sclerosis (FALS) are associated with copper/zinc superoxide dismutase (Cu/Zn-SOD) mutations, which are implicated in the death of motor neurons. Because Cu/Zn-SOD is present in high amounts in nigrostriatal dopaminergic neurons, we considered the possibility that FALS may be associated with subclinical nigrostriatal dopaminergic dysfunction. We used [18F]fluorodopa (FDOPA) and PET to study 14 FALS patients (50 +/- 11 years [mean +/- SD]): seven with (FALS-1) and seven without (FALS-0) Cu/Zn-SOD mutations. Fourteen age-matched normal volunteers (48 +/- 18 years) served as controls. Striato-occipital ratios (SORs) for the caudate and the putamen were calculated. Five of the 14 FALS patients had reduced striatal FDOPA uptake in the caudate nucleus, putamen, or both. Mean caudate SOR did not differ among FALS-1, FALS-0, and control subjects. Mean putamen SOR was significantly abnormal in FALS-0 but not in FALS-1 patients. These findings indicate that subclinical nigrostriatal dopaminergic dysfunction is present in some FALS patients and that FDOPA/PET abnormalities are more likely to be associated with FALS-0 status. This suggests that SOD mutations are less cytotoxic to dopaminergic than to motor neurons.

Adult↗

PubMed1996

Combined FDOPA and 3OMFD PET studies in Parkinson's disease.

UNLABELLED: PET has been used to quantify striatal 6-[18F]fluoro-L-dopa (FDOPA) uptake as a measure of presynaptic dopaminergic function. It has been suggested that the estimation of dopa-decarboxylation (DDC) rate, kD3, using a compartmental approach to dynamic FDOPA/PET data, can provide a better objective marker of parkinsonism. This modeling process, however, requires many assumptions to estimate DDC activity with acceptable errors. METHODS: We combined FDOPA 3-O-methyl-fluorodopa PET studies on three normal subjects and five Parkinson's disease patients. RESULTS: The contradicted modeling assumptions are: (a) the rate constants across the blood-brain barrier, KD1 and kD2, for 3OMFD and FDOPA were in similar range (ratio approximately equal to 1) and thus not equal to assumed values of KM1/KD1 of 2.3 derived from rat studies and applied to human FDOPA studies and (b) the KD1/kD2 ratio for frontal cortex was not equal to that for the striatum (0.70 +/- 0.15 versus 1.07 +/- 0.3; p < 0.002). Discriminant analyses indicate that simple estimates like the striatum-to-occipital ratio, or the graphically derived unidirectional transport rate constant (KiFD) separate normals from Parkinson's disease patients at least as accurately as estimates of striatal DDC activity (kD3). CONCLUSION: Measurements of striatal DDC activity with dynamic FDOPA/PET and compartmental modeling may be based on incorrect assumptions. Even though such complex models yield microparameters that may be applicable to certain clinical research demands, they may produce misleading results in other experimental settings.

Adult↗

PubMed1996

Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

UNLABELLED: We performed dynamic PET studies with fluorodopa (FDOPA) in 9 normal volunteers and 16 patients with Parkinson's disease to investigate the applicability of dopa decarboxylase (DDC) activity measurements as useful markers of the parkinsonian disease process. METHODS: From the 3-O-methyl-FDOPA (3OMFD)/PET studies, we obtained mean population values of the kinetic rate constants for 3OMFD (K1M = 0.0400 and k2M = 0.0420). We applied these values to calculate striatal DDC activity using the FDOPA compartmental model. We estimated k3D in this group using dynamic FDOPA-PET and population mean K1M and k2M values. We then applied the mean population K1M and k2M values to estimate k3D(pop) to a new group (6 normal volunteers and 11 patients) studied only with dynamic FDOPA-PET. In all FDOPA/PET studies, we calculated striatal uptake rate constants (KiFD) using a graphical method and also measured the striato-occipital ratio (SOR). RESULTS: Although DDC activity has been postulated as a precise indicator of presynaptic nigrostriatal dopaminergic function, KiFD and SOR provided better between-group discrimination than did estimates of striatal DDC activity. KiFD and k3D(pop) both correlated significantly with quantitative disease severity ratings, with a similar degree of accuracy (r = 0.69 and 0.63 for k3D(pop) and KiFD, respectively; p < 0.01). CONCLUSION: Although estimated striatal DDC activity correlates with clinical disability, this measure is comparably less effective for early diagnosis. We conclude that a simple estimate such as striatal KiFD is superior to k3D measurements for most clinical and research applications.

Brain↗

PubMed1996

Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

UNLABELLED: SPECT imaging of the dopamine transporter is now an alternative to PET in the quantification of nigrostriatal dopaminergic function. We compared [123I] beta CIT-FP/SPECT and [18F]FDOPA/PET in the assessment of nigrostriatal dopaminergic function in Parkinson's disease (PD) and normal aging. METHODS: We studied 12 mildly affected PD patients (mean age: 61.0 +/- 13.2 yr; H&Y Stage I-II) with both [123I] beta CIT-FP and [18F]FDOPA. Fifteen normal volunteers (mean age: 45.5 +/- 22.1 yr) served as controls for both tracers. We measured the striato-occipital ratio (SOR) for both tracers at approximately 100 min postinjection. RESULTS: We found a highly significant correlation between SOR measures obtained for both tracers (r = 0.79, p < 0.0001). In normal volunteers a significant age-related decline in striatal uptake was noted with [123I] beta CIT-FP (r = -0.56, p < 0.04) but not with [18F]FDOPA. SOR values for both tracers discriminated PD patients from controls with comparable accuracy (F[1,25] = 52.1 and 53.0, p < 0.0001 for [123I] beta CIT-FP and [18F]FDOPA, respectively). UPDRS motor ratings correlated with SOR values obtained by both imaging techniques (r = -0.69 and -0.60, p < 0.04 for [123I] beta CIT-FP and [18F]FDOPA, respectively). CONCLUSION: These results indicate that [123I] beta CIT-FP/SPECT can provide quantitative descriptors of presynaptic dopaminergic function comparable to those obtained with [18F]FDOPA/PET.

Adult↗

PubMed1996

Bladder wall radiation dose in humans from fluorine-18-FDOPA.

UNLABELLED: PET, in conjunction with 18F-fluorodopa (FDOPA), has become the standard technique to assess basal ganglia degeneration in patients with movement disorders. Based on published dosimetry data, the injected dose of FDOPA is limited to 111 Mbq (3 mCi) because of exposure to the bladder wall, which is the critical organ for such studies. These dosimetry studies are based on mathematical models for the bladder radioactivity accumulation and clearance when the subjects were asked to void approximately 2 hr after the intravenous injection of FDOPA. In this study, we improved the radiation dose estimate to the bladder wall using dynamic PET to image the bladder during the uptake phase as well as before and after voiding. METHODS: The subjects were tested on a new protocol. They were hydrated preinjection and given a first bladder void break at 40 min postinjection and a second void at the end of study at 120 min. RESULTS: The MIRD model, applied to the data collected from 10 adults of both sexes, yielded an average absorbed dose of 0.15 +/- 0.08 mGy/MBq (0.57 +/- 0.28 rad/mCi). CONCLUSION: This absorbed dose is significantly lower than previous estimates and allows for FDOPA injections up to 333 Mbq (9 mCi).

Adult↗

PubMed1996

Plasma vitamin A, zinc and selenium concentrations in children with acute and persistent diarrhoea.

Plasma zinc, selenium, and vitamin A concentrations in 25 children with persistent diarrhoea (PD) and acute diarrhoea (AD) were determined and compared with 25 age-matched control children. Plasma retinol concentrations (PRC) and plasma zinc concentrations (PZC) (3.92 micrograms/dL and 79.4 micrograms/dL respectively) were found to be significantly lower (p < 0.05) in children with PD. PZCs were also significantly reduced (p < 0.05) in children with AD. However, reduction in PZC was more in PD than that in AD. There was no significant difference in PSC in children with either types of diarrhoea as compared with the control group. The results of the study showed that there was deficiency of vitamin A and zinc in diarrhoeas which needs to be correlated for proper nutritional management.

Acute Disease↗

PubMed1995

Structure and evolution of the compact radio source in NGC 1275.

Investigations of the fine-scale structure in the compact nucleus of the radio source 3C 84 in NGC 1275 (New General Catalogue number) are reported. Structural monitoring observations beginning as early as 1976, and continuing to the present, revealed subluminal motions in a jet-like relatively diffuse region extending away from a flat-spectrum core. A counterjet feature was discovered in 1993, and very recent nearly simultaneous studies have detected the same feature at five frequencies ranging from 5 to 43 GHz. The counterjet exhibits a strong low-frequency cutoff, giving this region of the source an inverted spectrum. The observations are consistent with a physical model in which the cutoff arises from free-free absorption in a volume that surrounds the core but obscures only the counterjet feature. If such a model is confirmed, very-long-baseline radio interferometry observations can then be used to probe the accretion region, outside the radio jet, on parsec scales.

Journal Article↗

PubMed1995

Lid opening apraxia is associated with medial frontal hypometabolism.

We used [18F]fluorodeoxyglucose with positron emission tomography to explore the functional basis of lid opening apraxia (LOA). We studied four patients with LOA without associated pyramidal or extrapyramidal motor dysfunction (mean age 65.5 +/- 4.7 years). We compared measures of glucose metabolism with those calculated for 10 age-matched normal volunteers (mean age 60.6 +/- 11.4). All four patients demonstrated significant metabolic reductions (> 2 SD) in the medial frontal lobe: bilaterally in two, unilaterally in two. Significant abnormal unilateral metabolic reductions in the left basal ganglia were evident in two patients. These findings suggest that medial frontal lobe hypometabolism is associated with LOA. Abnormal striatofrontal interactions may be involved in the pathogenesis of this condition.

Aged↗

PubMed1995

The metabolic topography of idiopathic torsion dystonia.

We used [18F]fluorodeoxyglucose (FDG) and PET with a statistical model of regional metabolic covariation to study brain topographic organization in idiopathic torsion dystonia (ITD). We studied 11 patients with predominantly right-sided ITD and 11 age-matched controls, and measured global, regional cerebral and normalized metabolic rates for glucose (GMR, rCMRGlc, rCMRGlc/GMR). The Scaled Subprofile Model was applied to the combined rCMRGlc dataset to identify topographic covariance profiles associated with ITD. We found that global and regional metabolic rates were normal in ITD. The SSM analysis of the combined groups of ITD patients and normals revealed a significant topographic profile characterized by relative bilateral increases in the metabolic activity of the lateral frontal and paracentral cortices, associated with relative covariate hypermetabolism of the contralateral lentiform nucleus, pons and midbrain. Subject scores for this profile correlated significantly with Fahn-Marsden disease severity ratings (r = 0.67, P < 0.02). In contrast to parkinsonism, lentiform and thalamic metabolism were dissociated in dystonia. We conclude that ITD is characterized by relative metabolic overactivity of the lentiform nucleus and premotor cortices. The presence of lentiform thalamic metabolic dissociation suggests that in this disorder hyperkinetic movements may arise through excessive activity of the direct putameno-pallidal inhibitory pathway.

Adult↗

PubMed1995

Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.

Early-stage Parkinson's disease (EPD) is often clinically asymmetric. We used 18F-fluorodeoxyglucose (FDG) and PET to assess whether EPD can be detected by a characteristic pattern of regional metabolic asymmetry. To identify this pattern, we studied 10 EPD (Hoehn and Yahr stage I) patients (mean age 61.1 +/- 11.1 years) using 18F-FDG and PET to calculate regional metabolic rates for glucose. The scaled subprofile model (SSM) was applied to metabolic asymmetry measurements for the combined group of EPD patients and normal subjects to identify a specific covariation pattern that discriminated EPD patients from normal subjects. To determine whether this pattern could be used diagnostically, we studied a subsequent group of five presumptive EPD patients (mean age 50.9 +/- 18.3), five normal subjects (mean age 44.6 +/- 15.3), and nine patients with atypical drug-resistant early-stage parkinsonism (APD) (mean age 44.6 +/- 14.0). In each member of this prospective cohort, we calculated the expression of the EPD-related covariation pattern (subject scores) on a case-by-case basis. We also studied 11 of the EPD patients, five patients with APD, and 10 normal subjects with 18F-fluorodopa (FDOPA) and PET to measure presynaptic nigrostriatal dopaminergic function, and we assessed the accuracy of differential diagnosis with both PET methods using discrimination analysis. SSM analysis disclosed a significant topographic contrast profile characterized by covariate basal ganglia and thalamic asymmetries. Subject scores for this profile accurately discriminated EPD patients from normal subjects and APD patients (p < 0.0001). Group assignments into the normal or parkinsonian categories with FDG/PET were comparable to those achieved with FDOPA/PET, although APD and EPD patients were not differentiable by the latter method. Metabolic brain imaging with FDG/PET may be useful in the differential diagnosis of EPD.

Adult↗

PubMed1995

Cerebral metabolic topography in unilateral temporal lobe epilepsy.

OBJECTIVE: Fluorodeoxyglucose positron emission tomography (FDG-PET) studies of temporal lobe epilepsy (TLE) generally report interictal hypometabolism in the vicinity of the seizure focus. Yet, other evidence suggests that interictal metabolic abnormalities might extend to remote brain areas. We used FDG-PET to evaluate metabolism in selected regions distant from the focus in TLE. SUBJECTS: Twenty adult patients with medically intractable TLE were selected by criteria favoring a unilateral mesiobasal temporal focus. Structural imaging in this sample were normal except for medial temporal sclerosis in 13 patients. Twenty normal volunteers were controls. DESIGN: PET imaging was performed interictally. Regional glucose metabolism normalized by global metabolism was analyzed using t tests and correlation analysis. RESULTS: Ipsilateral to the seizure focus, metabolism was depressed compared with normal in the temporal pole (p = 0.001), but relatively elevated in the mesiobasal region (p = 0.005). Contralateral to the focus, metabolism was elevated in lateral temporal cortex (p = 0.0003) and mesiobasal regions (p = 0.0001). Metabolic correlation between ipsilateral and contralateral mesiobasal regions was similar in normal subjects (r = 0.74) and patients (r = 0.68). In contrast, correlations were abnormal between temporal poles and other temporal lobe subregions, both ipsilateral and contralateral to the seizure focus. CONCLUSIONS: Relative to normal values, both elevations and depressions of metabolism exist interictally in TLE. Such abnormalities, and accompanying changes in interregional correlations, may have wide spatial distribution. These findings are atypical among PET studies but are consistent with other physiologic, anatomic, and neuropsychological investigations of TLE.

Adolescent↗

PubMed1995

Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.

UNLABELLED: Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identify an abnormal regional metabolic covariance pattern in Parkinson's disease (PD). To examine the potential use of this covariance pattern as a metabolic imaging marker for PD, we describe the Topographic Profile Rating (TPR), which is a method for calculating subject scores for this pattern in individual PD patients. We then assess the relationship between these metabolic measures and objective independent disease severity ratings. METHODS: Two independent groups of PD patients were studied with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/- 12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 patients (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2). The regional cerebral metabolic rates for glucose (rCMRGlc) in all patients in each group were measured. TPR was used to calculate subject scores for the disease-related covariance pattern on a patient-by-patient basis. RESULTS: In both PD patient groups, subject scores correlated with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p < 0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesia (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidity (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not with tremor. CONCLUSION: These findings indicate that regional metabolic covariance patterns are robust imaging markers of disease severity. FDG-PET may be useful clinically in assessing parkinsonian disability and disease progression.

Adult↗

PubMed1994

The metabolic topography of parkinsonism.

We used [18F]fluorodeoxyglucose/positron emission tomography (18F-FDG/PET) and a statistical model of regional covariation to study brain topographic organization in parkinsonism. We studied 22 patients with Parkinson's disease (PD), 20 age-matched normal volunteers, and 10 age- and severity-matched patients with presumed striatonigral degeneration (SND). We used FDG/PET to calculate global, regional, and normalized metabolic rates for glucose (GMR, rCMRglc, rCMRglc/GMR). Metabolic parameters in the three groups were compared using an analysis of variance, with a correction for multiple comparisons, and discriminant analysis. The scaled subprofile model (SSM) was applied to the combined rCMRglc dataset to identify topographic covariance profiles that distinguish PD patients from SND patients and normals. GMR, rCMRglc, and rCMRglc/GMR were normal in PD; caudate and lentiform rCMRglc/GMR was reduced in the SND group (p < 0.01). SSM analysis of the combined group of patients and normals revealed a significant topographic profile characterized by increased metabolic activity in the lentiform nucleus and thalamus associated with decreased activity in the lateral frontal, paracentral, inferior parietal, and parietooccipital areas. Individual subject scores for this profile were significantly elevated in PD patients compared with normals and SND patients (p < 0.001) and discriminated the three groups. In the PD group, subject scores for this factor correlated with individual subject Hoehn and Yahr (H & Y) scores (p < 0.02), and with quantitative rigidity (p < 0.01) and bradykinesia (p < 0.03) ratings, but not with tremor ratings. SSM analysis of right-left metabolic asymmetries yielded a topographic contrast profile that accurately discriminated mildly affected PD patients (H & Y Stage I) from normals. Our findings demonstrate that abnormal topographic covariance profiles exist in parkinsonism. These profiles have potential clinical application as neuroimaging markers in parkinsonism.

Adult↗

PubMed1994

Quantitative brain FDG/PET studies using dynamic aortic imaging.

Positron emission tomography (PET) measurements of cerebral glucose utilization using 18F-fluorodeoxyglucose (FDG) are a useful tool in the investigation of localized brain function in normal and disease states. A major impediment to the application of FDG/PET in clinical investigation has been the need for arterial blood sampling to quantify cerebral glucose metabolism (CMRGlc). Qualitative studies, though informative in a variety of clinical settings, are of limited value for research applications and do not utilize the inherent quantitative nature of PET. We present a novel PET technique employing a whole-body PET tomograph with abdominal aortic imaging from 0 to 30 min as an alternative to arterial blood sampling to obtain the input function for cerebral metabolic rate calculations. Two or three arterial samples taken during the 10-45 min period were used to scale and extend the blood curve and the brain was imaged from 35-55 min post-injection. We performed 12 studies in which both arterial blood sampling and aortic scans were obtained. We found the correlation of global metabolic rates (GMR) when comparing the two techniques to be extremely high (R2 = 0.99). This suggests that the use of dynamic aortic imaging is less invasive and a viable alternative to arterial blood sampling in quantitative FDG/PET imaging.

Algorithms↗

PubMed1994

Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism.

We used 18F-fluorodeoxyglucose and PET to study a 23-year-old woman with alternating hemichorea and primary antiphospholipid syndrome. There were three PET studies: (1) during an episode of right hemichorea, (2) during an asymptomatic period 6 months later, and (3) during an episode of left hemichorea occurring 2 months after that. In each study, we calculated normalized regional glucose metabolism for the caudate and lentiform nuclei and compared these values with those calculated in 12 normal volunteer subjects (mean age, 35.3 +/- 9.0). The following results were obtained: (1) during right hemichorea, left lentiform metabolism was increased by 19% (> 3 SD); (2) during the asymptomatic period, right caudate metabolism was increased by 20% (> 3 SD), and right lentiform and left striatal metabolism were normal; and (3) during left hemichorea, right caudate and lentiform metabolism were both elevated by 33% (> 3 SD). During this episode, left caudate metabolism was elevated by 20% (> 2 SD); left lentiform metabolism was normal. These results suggest that hemichorea in primary antiphospholipid syndrome may be associated with contralateral striatal hypermetabolism that may also be present during asymptomatic periods.

Adult↗

PubMed1994

Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome.

We estimated regional and global metabolic rates for glucose using 18F-fluorodeoxyglucose (FDG) and PET in six patients with hemiparkinsonism-hemiatrophy syndrome (HPHA; mean age, 41.0 +/- 12.4 years). We used 18F-fluorodopa (FDOPA) and PET in two patients to quantify presynaptic nigrostriatal dopaminergic function. We compared measures of brain glucose metabolism and striatal FDOPA uptake with those calculated for 10 age-matched normal volunteers (mean age, 35.1 +/- 8.0 years) and 10 patients with typical unilateral Parkinson's disease (unilat-PD; mean age, 58.2 +/- 13.8 years). All six HPHA patients demonstrated significant metabolic reductions (> 3 SD) in the contralateral basal ganglia or frontal cortex as compared with normal control values. Mean normalized glucose metabolism was reduced in the contralateral caudate and lentiform nuclei (p < 0.005) as compared with that in unilat-PD and normal controls. In both patients studied with FDOPA, contralateral striatal uptake was significantly reduced (> 3 SD) as compared with normal control values. These results suggest that the clinical manifestations of HPHA arise through a combination of pre- and postsynaptic nigrostriatal dopaminergic dysfunction. FDG and PET may be useful in differentiating this disorder from typical unilat-PD.

Adult↗

PubMed1994

Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.

UNLABELLED: PET has been used to quantify striatal 6-[18F]fluoro-L-dopa (FDOPA) uptake as a measure of presynaptic dopaminergic function. Striatal FDOPA uptake rate constants (Ki) can be calculated using dynamic PET imaging with measurements of the plasma FDOPA input function determined either directly or by several estimation procedures. METHODS: We assessed the comparative clinical utility of these methods by calculating the striato-occipital ratio (SOR) and striatal Ki values in 12 patients with mild to moderate PD and 12 age-matched normal volunteers. The plasma FDOPA time-activity curve (KiFD); the plasma 18F time-activity curve (KiP); the occipital time-activity curve (KiOCC); and a simplified population-derived FDOPA input function (KiEFD) were used to calculate striatal Ki. RESULTS: Mean values for all striatal Ki estimates and SOR were significantly lower in the PD group. Although all measured parameters discriminated PD patients from normals, KiFD and KiEFD provided the best between-group separation. KiFD, KiEFD and KiOCC measures correlated significantly with quantitative disease severity ratings, although KiFD predicted quantitative clinical disability most accurately. CONCLUSION: These results suggest that KiFD may be an optimal marker of the parkinsonian disease process. KiEFD may be a useful alternative to KiFD for most clinical research applications.

Adult↗